473 related articles for article (PubMed ID: 12454511)
1. CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.
Slater EP; Langer P; Fendrich V; Habbe N; Chaloupka B; Matthäi E; Sina M; Hahn SA; Bartsch DK
Fam Cancer; 2010 Sep; 9(3):335-43. PubMed ID: 20195775
[TBL] [Abstract][Full Text] [Related]
3. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
4. INK4/ARF germline alterations in pancreatic cancer patients.
Ghiorzo P; Pastorino L; Bonelli L; Cusano R; Nicora A; Zupo S; Queirolo P; Sertoli M; Pugliese V; Bianchi-Scarrà G
Ann Oncol; 2004 Jan; 15(1):70-8. PubMed ID: 14679123
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
7. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
9. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
10. Update of familial pancreatic cancer in Germany.
Bartsch DK; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Rieder H
Pancreatology; 2001; 1(5):510-6. PubMed ID: 12120230
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
[TBL] [Abstract][Full Text] [Related]
15. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
[TBL] [Abstract][Full Text] [Related]
16. BRCA2 germline mutations in familial pancreatic carcinoma.
Hahn SA; Greenhalf B; Ellis I; Sina-Frey M; Rieder H; Korte B; Gerdes B; Kress R; Ziegler A; Raeburn JA; Campra D; Grützmann R; Rehder H; Rothmund M; Schmiegel W; Neoptolemos JP; Bartsch DK
J Natl Cancer Inst; 2003 Feb; 95(3):214-21. PubMed ID: 12569143
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
20. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
